Lululemon Athletica Forecast, price target & analysts
Lululemon Athletica Target price 2025 - Analyst rating & recommendation
Lululemon Athletica Classifications & Recommendation:
Lululemon Athletica Price Target
| Target Price | $407.83 |
| Price | $358.97 |
| Potential | 13.61% |
| Number of Estimates | 30 |
| 30 Analysts have issued a price target Lululemon Athletica 2026 . The average Lululemon Athletica target price is $407.83. This is 13.61% higher than the current stock price. The highest price target is $500.00 39.29% , the lowest is $194.00 45.96% . | |
| A rating was issued by 36 analysts: 20 Analysts recommend Lululemon Athletica to buy, 11 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Lululemon Athletica stock has an average upside potential 2026 of 13.61% . Most analysts recommend the Lululemon Athletica stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
31 Analysts have issued a sales forecast Lululemon Athletica 2025 . The average Lululemon Athletica sales estimate is $10.5b . This is 3.53% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.6b 3.95% , the lowest is $10.4b 2.23% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $9.6b | 18.60% |
|---|---|---|
| 2025 | $10.5b | 9.58% |
| 2026 | $11.3b | 7.29% |
| 2027 | $12.3b | 8.55% |
| 2028 | $13.1b | 6.54% |
| 2029 | $13.7b | 4.91% |
25 Analysts have issued an Lululemon Athletica EBITDA forecast 2025. The average Lululemon Athletica EBITDA estimate is $2.9b . This is 0.02% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 1.95% , the lowest is $2.8b 3.30% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $2.6b | 27.72% |
|---|---|---|
| 2025 | $2.9b | 11.74% |
| 2026 | $3.1b | 6.93% |
| 2027 | $3.3b | 7.78% |
| 2028 | $3.6b | 7.04% |
| 2029 | $3.7b | 4.84% |
EBITDA Margin
| 2024 | 26.89% | 7.69% |
|---|---|---|
| 2025 | 27.42% | 1.96% |
| 2026 | 27.33% | 0.33% |
| 2027 | 27.14% | 0.70% |
| 2028 | 27.27% | 0.48% |
| 2029 | 27.25% | 0.07% |
10 Lululemon Athletica Analysts have issued a net profit forecast 2025. The average Lululemon Athletica net profit estimate is $1.7b . This is 3.39% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.8b 4.37% , the lowest is $1.7b 0.72% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $1.5b | 82.63% |
|---|---|---|
| 2025 | $1.7b | 17.37% |
| 2026 | $1.9b | 6.88% |
| 2027 | $2.0b | 9.64% |
| 2028 | $2.4b | 15.41% |
| 2029 | $2.6b | 11.59% |
Net Margin
| 2024 | 15.49% | 53.99% |
|---|---|---|
| 2025 | 16.60% | 7.14% |
| 2026 | 16.53% | 0.42% |
| 2027 | 16.70% | 1.03% |
| 2028 | 18.09% | 8.32% |
| 2029 | 19.24% | 6.36% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
10 Analysts have issued a Lululemon Athletica forecast for earnings per share. The average Lululemon Athletica <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $14.32 . This is 3.39% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $14.46 4.40% , the lowest is $13.95 0.72% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $12.20 | 82.63% |
|---|---|---|
| 2025 | $14.32 | 17.38% |
| 2026 | $15.30 | 6.84% |
| 2027 | $16.78 | 9.67% |
| 2028 | $19.37 | 15.44% |
| 2029 | $21.61 | 11.56% |
P/E ratio
| Current | 25.93 | 54.68% |
|---|---|---|
| 2025 | 25.07 | 3.32% |
| 2026 | 23.45 | 6.46% |
| 2027 | 21.39 | 8.78% |
| 2028 | 18.54 | 13.32% |
| 2029 | 16.61 | 10.41% |
Based on analysts' sales estimates for 2025, the Lululemon Athletica stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.18 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.15 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.33 | 29.94% |
|---|---|---|
| 2025 | 4.18 | 3.50% |
| 2026 | 3.89 | 6.79% |
| 2027 | 3.59 | 7.88% |
| 2028 | 3.37 | 6.14% |
| 2029 | 3.21 | 4.68% |
P/S ratio
| Current | 4.29 | 30.48% |
|---|---|---|
| 2025 | 4.15 | 3.41% |
| 2026 | 3.87 | 6.79% |
| 2027 | 3.56 | 7.88% |
| 2028 | 3.34 | 6.14% |
| 2029 | 3.19 | 4.68% |
Lululemon Athletica...
Current Lululemon Athletica Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer | Outperform ➜ Outperform | Unchanged | Feb 07 2025 |
| Evercore ISI Group | Outperform ➜ Outperform | Unchanged | Jan 28 2025 |
| Keybanc | Overweight ➜ Overweight | Unchanged | Jan 23 2025 |
| Barclays | Equal-Weight ➜ Equal-Weight | Unchanged | Jan 16 2025 |
| JP Morgan | Overweight ➜ Overweight | Unchanged | Jan 16 2025 |
| Raymond James | Outperform ➜ Outperform | Unchanged | Jan 15 2025 |
| Morgan Stanley | Overweight ➜ Overweight | Unchanged | Jan 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Oppenheimer: Outperform ➜ Outperform
|
Feb 07 2025 |
|
Unchanged
Evercore ISI Group: Outperform ➜ Outperform
|
Jan 28 2025 |
|
Unchanged
Keybanc: Overweight ➜ Overweight
|
Jan 23 2025 |
|
Unchanged
Barclays: Equal-Weight ➜ Equal-Weight
|
Jan 16 2025 |
|
Unchanged
JP Morgan: Overweight ➜ Overweight
|
Jan 16 2025 |
|
Unchanged
Raymond James: Outperform ➜ Outperform
|
Jan 15 2025 |
|
Unchanged
Morgan Stanley: Overweight ➜ Overweight
|
Jan 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
